BioCentury
ARTICLE | Financial News

Silverback announces series A extension

September 28, 2018 7:27 PM UTC

Cancer and autoimmune company Silverback Therapeutics Inc. (Seattle, Wash.) raised an extension of its series A round on Sept. 19, bringing the round's total to $47.5 million. The round was led by existing investor OrbiMed. New investors Celgene Corp. (NASDAQ:CELG) and Alexandria Venture Investments also participated...

BCIQ Company Profiles

Silverback Therapeutics Inc.